Methotrexat Ebewe

Methotrexate disodium, the active ingredient in Methotrexat Ebewe, is an antimetabolite presented as a sterile solution for injection for intramuscular, intravenous, and subcutaneous use. It is employed in the management of rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma, and gestational trophoblastic disease in appropriate patients.

GNH USA supplies Methotrexat Ebewe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importation. Products are delivered through reliable logistics networks ensuring timely availability.

Methotrexate disodium is used in several autoimmune and oncologic conditions where inhibition of folate metabolism is required.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: improves skin lesions and decreases plaque formation. - Acute lymphoblastic leukemia: induces remission by inhibiting malignant cell proliferation. - Non‑Hodgkin lymphoma: contributes to tumor control through cytotoxic effects. - Gestational trophoblastic disease: facilitates resolution of trophoblastic tissue.

Methotrexate disodium may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting - Stomatitis or mouth ulcers - Fatigue or weakness - Alopecia (hair loss) - Mild elevation of liver enzymes - Diarrhea

Serious or Rare Side Effects: - Bone marrow suppression leading to pancytopenia - Severe hepatotoxicity or hepatic fibrosis - Pulmonary toxicity such as interstitial pneumonitis - Life‑threatening infections due to immunosuppression - Renal impairment or acute kidney injury - Severe cutaneous reactions (e.g., Stevens‑Johnson syndrome)

Before initiating therapy with Methotrexat Ebewe, several precautions and monitoring measures should be observed.

- Pregnancy contraindication: avoid use in pregnancy (Category X) due to teratogenic risk. - Breastfeeding restriction: do not breastfeed while receiving treatment. - Baseline laboratory tests: obtain complete blood count, liver and renal function before therapy. - Regular monitoring: schedule periodic CBC, liver enzymes, and renal function assessments. - Drug interactions: review concomitant medications for potential additive toxicity. - Store at controlled room temperature: keep in original container, protect from light and moisture.

Methotrexate disodium has notable interactions that may require avoidance or careful monitoring.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Penicillins and other β‑lactam antibiotics: enhance bone‑marrow suppression. - Live vaccines: risk of severe infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect methotrexate absorption. - Oral contraceptives: reduced efficacy, consider alternative contraception. - Diuretics: may impair renal clearance and increase toxicity.